Document is current

Article History

Received: 13 January 2021

Accepted: 11 February 2021

First Online: 14 April 2021

Declarations

:

: The study was performed in accordance with the International Conference on Harmonization guidelines and Declaration of Helsinki 1964 and its amendments. The Institutional Review Board of each study site approved the study protocol, information brochure, and the informed consent form before study initiation.

: Informed consent was obtained from all individual participants included in the study.

: Patients provided informed consent to regarding publishing their data.

: <b>GS. Falchook</b> reports receiving grants from Eli Lilly and Company during the conduct of the study. He also received grants from 3-V Biosciences, Abbisko, ADC Therapeutics, Aileron, American Society of Clinical Oncology, Amgen, ARMO, Beigene, Bioatla, Bioinvent, Biothera, Bicycle, Celldex, Celgene, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, grants and other from EMD Serono, Epizyme, Exelixis, grants and other from Fujifilm, Genmab, GSK, Hutchison MediPharma, from Igynta, Incyte, Jacobio, Jouce, Kolltan, Loxo, MedImmune, grants and other from Millenium, Merck, miRNA Therapeutics, NIH, Novartis, Oncomed, Oncorus, Oncothyreon, from Poseida, Precision Oncology, Prelude, Regeneron, Rgenix, Ribon, Sapience, Strategia, Syndax, Synthorx, Taiho, Takeda, Tesaro, Tocagen, Turning Point Therapeutics, U.T. MD Anderson Cancer Center, Vegenics, Xencor, other from Wolters-Kluver, other from Sarah Cannon Research Institute, other from Total Health Conferencing, other from Rocky Mountain Oncology Society. He also received Royalties (self): Wolters Kluwer (2014-present) Advisory role (to institution): Fujifilm (2018) Údvisory role (self): EMD Serono (2010, 2011) Travel (self, for work or research related to institution): Bristol-Myers Squibb (2015), EMD Serono (2011, 2012, 2013), Fujifilm (2018), Millennium (2013), Sarah Cannon Research Institute Speakers honorarium for CME: Total Health Conferencing (2019), Rocky Mountain Oncology Society (2020) Research funding (to institution) from Ó-V Biosciences, Abbisko, Abbvie, ADC Therapeutics, Aileron, American Society of Clinical Oncology, Amgen, ARMO, AstraZeneca, BeiGene, Bioatla, Bioinvent, Biothera, Bicycle, Celldex, Celgene, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly and Company, EMD Serono, Epizyme, Exelixis, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Jounce, Kolltan, Loxo, MedImmune, Millennium, Merck, miRNA Therapeutics, National Institutes of Health, Novartis, OncoMed, Oncorus, Oncothyreon, Poseida, Precision Oncology, Prelude, Regeneron, Rgenix, Ribon, Sapience, Strategia, Syndax, Synthorx, Taiho, Takeda, Tarveda, Tesaro, Tocagen, Turning Point Therapeutics, U.T. MD Anderson Cancer Center, Vegenics, and Xencor.<b>M. Peeters</b> reports receiving advisory fee from Eli Lilly and Company.<b>S. Rottey, LY. Dirix, R. Obermannova,</b> and <b>JE. Cohen</b> have no conflicts to disclose.<b>R. Perets</b> reports receiving personal fees from BiolineRx and Karyopharm Therapeutics.<b>RD. Carvajal</b> reports receiving personal fees and other from BMS, Incyte, Immunocore, and Merck Roche/Genentech; personal fees from Castle Biosciences, Compugen, Foundation Medicine, I-Mab, PureTech, Sanofi Genzyme, Sorrento Therapeutics, Aura Biosciences, Chimeron, and Rgenix; other from Amgen, Novartis, Pfizer, AstraZeneca, Bellicum, Plexxikon, Mirati, Macrogenics, Corvus, Bayer, Eli Lilly and Company, and Astellis.<b>J. Sabari</b> reports receiving personal fees from AstraZeneca, Janssen, and Pfizer.<b>DA. Peterson, S. Chapman, W. Zhang,</b> and <b>B. Calderon</b> are full-time employees of Eli Lilly and Company.<b>RS. Frommer</b> reports receiving personal fees from MSD, BMS, Roche, Novartis, Clovis oncology, and Astra Zeneca.<b>TM. Bauer</b> reports receiving grants from Eli Lilly and Company during the conduct of the study; grants from Daiichi Sankyo, Medpacto, Incyte, Mirati Therapeutics, MedImmune, Abbvie, AstraZeneca, MabVax, Stemline Therapeutics, Merck, Eli Lilly and Company, GlaxoSmithKline, Novartis, Genentech, Deciphera, Merrimack, Immunogen, Millennium, Phosplatin Therapeutics, Calithera Biosciences, Kolltan Pharmaceuticals, Principa Biopharma, Peleton, Immunocore, Roche, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Onyx, Sanofi, Boehringer-Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance BioScience, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Foundation Medicine, and ARMO Biosciences; grants and other from Leap Therapeutics; grants and non-financial support and other from Ignyta and Moderna Therapeutics; grants, personal fees and other from Pfizer; grants, personal fees and non-financial support from Loxo and Bayer; personal fees and non-financial support from Guardant Health; personal fees from Exelesis.<b>JS. Wang</b> reports receiving research funding to institution from Genentech, Vedanta Biosciences, Relay Therapeutics, Synthorx, Ribon Therapeutics, Clovis Pharma, Xencor, Black Diamond Therapeutics, Vigeo Therapeutics, Qilu Puget Sound Biotherapeutics, Daiichi Sankyo Pharma, Cyteir Therapeutics, Bicycle Therapeutics, Kymab, Prelude Therapeutics, ADC Therapeutics, Revolution Medicines, Klus Pharma, Janssen R&D, Birdie Biopharmaceuticals, Merck, Jacobio Pharmaceuticals, MacroGenics, TopAlliance Biosciences, Moderna, Agenus, Boehringer Ingelheim, Eli Lilly and Company, Tesaro, GlaxoSmithKline, Stemline Therapeutics, BioNTech, Hutchinson MediPharma, Evelo Biosciences, Ignyta, EMD Serono, Novartis Pharmaceuticals, Loxo Oncology, Acerta Pharma, Portola Pharmaceuticals, Celgene Corporation, Taiho Oncology, LSK BioPartners, Olema Pharmaceuticals, and Phoenix Molecular Designs; personal fees and AstraZeneca, H3 Biomedicine, and Syndax.